Jay Crowley, FDA's Unique Device Identification Regulation Architect, to Host UDI Compliance Webinar

SANTA BARBARA, CA–(Marketwired – Jan 8, 2014) – USDM Life Sciences, a leading global regulatory consulting firm in the life sciences industry, is pleased to announce the FDA’s UDI regulation developer, Jay Crowley will host his first complimentary webinar for the life sciences company. Crowley is now Vice President of USDM Life Sciences Unique Device Identification (UDI) practice.

The webinar will outline what the UDI final rule means for medical device companies, offer tips for successful UDI compliance, address industry concerns and answer any questions participants have about UDI. The presentation is scheduled for Thursday, January 16^th at 11 a.m. PST. 

As Senior Advisor for Patient Safety in the Food and Drug Administration’s Center for Devices and Radiological Health, Crowley developed the framework and authored key requirements for the FDA’s Unique Device Identification system. Crowley also led the team responsible for the development and implementation of UDI requirements.

Crowley held a variety of positions during his nearly 27 years at the FDA, including work with design control regulations to reduce the chance of human errors with medical devices, patient safety and adverse event reporting. Crowley also worked in the Office of the Commissioner of the FDA, and the Office of Compliance at the FDA.

At USDM Life Sciences, Crowley focuses exclusively on providing business process, technology and compliance solutions for the regulated life science industry. 

About USDM Life Sciences:
USDM Life Sciences is a leading global regulatory consulting firm providing compliance, validation, qualification, quality, auditing and information technology services via project teams and staff augmentation to our clients in the medical device, biotechnology, biologics, diagnostics and pharmaceutical industries. USDM Life Sciences has more than 13 years of experience supplying our clients in the life science industry with compliance services during each phase of their drug and product development cycle while partnering with best of breed organizations to help companies simplify, unify and optimize their business and compliance objectives. For more information, please visit www.usdm.com.